Takeda Pharmaceutical Company Profile (OTCMKTS:TKPYY)

About Takeda Pharmaceutical (OTCMKTS:TKPYY)

Takeda Pharmaceutical logoTakeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases, digestive system drugs, hormonal agents, osteoporosis drugs, antibiotic agents, allergy medications, vitamin drops and vaccines, among others. The Healthcare segment manufactures and sells general drugs and medicines, as well as quasi drugs. The Others segment is involved in the manufacture and sale of reagents, clinical diagnostics and chemical products. As of March 31, 2014, the Company had 146 subsidiaries and 17 associated companies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:TKPYY
  • CUSIP: N/A
  • Web: www.takeda.com
Capitalization:
  • Market Cap: $40.91737 billion
  • Outstanding Shares: 1,560,000,000
Average Prices:
  • 50 Day Moving Avg: $25.37
  • 200 Day Moving Avg: $23.18
  • 52 Week Range: $19.96 - $26.35
P/E:
  • Trailing P/E Ratio: 39.10
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $15.61 billion
  • Price / Sales: 2.58
  • Book Value: $10.94 per share
  • Price / Book: 2.36
Profitability:
  • EBIDTA: $4.71 billion
  • Net Margins: 7.86%
  • Return on Equity: 9.76%
  • Return on Assets: 4.88%
Debt:
  • Debt-to-Equity Ratio: 0.36%
  • Current Ratio: 1.73%
  • Quick Ratio: 1.50%
Misc:
  • Average Volume: 39,661 shs.
  • Beta: 0.46
 

Frequently Asked Questions for Takeda Pharmaceutical (OTCMKTS:TKPYY)

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the OTCMKTS under the ticker symbol "TKPYY."

Who are some of Takeda Pharmaceutical's key competitors?

Who are Takeda Pharmaceutical's key executives?

Takeda Pharmaceutical's management team includes the folowing people:

  • Yasuchika Hasegawa, Chairman of the Board
  • Christophe Weber, President, Chief Executive Officer, Representative Director
  • Shinji Honda, President of Subsidiary, Corporate Strategy Office, Director
  • Andrew S. Plump, Chief Medical & Scientific Officer, Director
  • Masato Iwasaki, President of Japan Pharma Business Unit, Director
  • Yasuhiko Yamanaka, Director
  • Emiko Azuma, Independent Director
  • Jean-Luc Butel, Independent Director
  • Yoshiaki Fujimori, Independent Director
  • Koji Hatsukawa, Independent Director

How do I buy Takeda Pharmaceutical stock?

Shares of Takeda Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Takeda Pharmaceutical's stock price today?

One share of Takeda Pharmaceutical stock can currently be purchased for approximately $25.77.


MarketBeat Community Rating for Takeda Pharmaceutical (OTCMKTS TKPYY)
Community Ranking:  1.4 out of 5 ()
Outperform Votes:  16 (Vote Outperform)
Underperform Votes:  42 (Vote Underperform)
Total Votes:  58
MarketBeat's community ratings are surveys of what our community members think about Takeda Pharmaceutical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Takeda Pharmaceutical (OTCMKTS:TKPYY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: N/A

Analysts' Ratings History for Takeda Pharmaceutical (OTCMKTS:TKPYY)
Show:
DateFirmActionRatingPrice TargetDetails
1/31/2017Canaccord GenuityReiterated RatingBuyView Rating Details
(Data available from 6/27/2015 forward)

Earnings

Earnings History for Takeda Pharmaceutical (OTCMKTS:TKPYY)
Earnings by Quarter for Takeda Pharmaceutical (OTCMKTS:TKPYY)
Earnings History by Quarter for Takeda Pharmaceutical (OTCMKTS TKPYY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2014$0.21$4.02 billionViewN/AView Earnings Details
2/5/2014Q4$0.29ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Takeda Pharmaceutical (OTCMKTS:TKPYY)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Takeda Pharmaceutical (OTCMKTS:TKPYY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Takeda Pharmaceutical (OTCMKTS:TKPYY)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Takeda Pharmaceutical (OTCMKTS:TKPYY)
Latest Headlines for Takeda Pharmaceutical (OTCMKTS:TKPYY)
Source:
DateHeadline
finance.yahoo.com logoUPDATE 1-Seattle Genetics, Takeda lymphoma drug success fails to impress investors
finance.yahoo.com - June 27 at 9:07 AM
rttnews.com logoTakeda, Seattle Genetics Report Positive Results From Phase 3 ECHELON-1 Trial
www.rttnews.com - June 26 at 7:47 AM
finance.yahoo.com logoSeattle Genetics, Takeda lymphoma drug succeeds late-stage trial
finance.yahoo.com - June 26 at 7:47 AM
finance.yahoo.com logoWhy Lupron Could Continue to Generate Steady Revenue
finance.yahoo.com - June 14 at 10:11 AM
finance.yahoo.com logoHarrington Discovery Institute at University Hospitals Opens Call for Harrington Rare Disease Scholar Award
finance.yahoo.com - May 25 at 5:04 AM
finance.yahoo.com logoTakeda and Marvel Custom Solutions Launch the Latest Adventure of the IBD Unmasked Super Hero Squad in Celebration of World IBD Day 2017
finance.yahoo.com - May 19 at 1:12 PM
finance.yahoo.com logoTakeda Announces American Psychiatric Association (APA) Innovation Zone Activities
finance.yahoo.com - May 19 at 1:12 PM
finance.yahoo.com logoThis $3,000 G-Shock Is Inspired by Samurai Armor
finance.yahoo.com - May 15 at 7:24 PM
finance.yahoo.com logoIsrael's BiomX raises $24 mln in private funding round
finance.yahoo.com - May 15 at 8:57 AM
finance.yahoo.com logoEGW Buys Tokyo Tower for $265 Million With Korean Investor Funds
finance.yahoo.com - May 9 at 10:03 AM
finance.yahoo.com logoTakeda and GammaDelta Therapeutics Announce Collaboration to Advance Tissue-derived gamma delta (γδ) T Cells
finance.yahoo.com - May 9 at 10:03 AM
finance.yahoo.com logoNew Real-World Analyses Support Effectiveness and Safety of Entyvio® (vedolizumab) for Ulcerative Colitis and Crohn's Disease
finance.yahoo.com - May 8 at 7:44 PM
finance.yahoo.com logoNew Real-World Analyses Support Effectiveness and Safety of Entyvio(R) (vedolizumab) for Ulcerative Colitis and Crohn's Disease
finance.yahoo.com - May 8 at 7:44 PM
reuters.com logoBRIEF-Takeda announces FDA accelerated approval of ALUNBRIG
www.reuters.com - April 28 at 10:51 PM
finance.yahoo.com logoTakeda and Harrington Discovery Institute at University Hospitals Announce a Collaboration to Advance the Development of Rare Disease Therapeutics
finance.yahoo.com - April 27 at 9:29 PM
finance.yahoo.com logoRaleigh's PRA Health Sciences clocks double-digit growth in first quarter
finance.yahoo.com - April 26 at 3:18 PM
finance.yahoo.com logo[$$] Demands of disease drive vaccine science
finance.yahoo.com - April 19 at 8:48 AM
finance.yahoo.com logoTakeda Pharmaceutical Company Limited -- Moody's: Japan economic momentum building, on the back of rising exports and expected fiscal support
finance.yahoo.com - April 18 at 8:47 AM
finance.yahoo.com logoTakeda's largest study brings dengue vaccine step closer
finance.yahoo.com - April 13 at 10:58 AM
reuters.com logoBRIEF-Takeda Pharmaceutical says splitting off partial Takeda Development Center Japan businesses to unit and plans JV with PRA Health Sciences
www.reuters.com - April 7 at 1:01 PM
us.rd.yahoo.com logoTakeda’s Dengue Vaccine Candidate Elicited Broad Immune Responses in Children and Adolescents Living in Dengue-Endemic Areas; Interim Phase 2 Analysis Published in The Lancet Infectious Diseases
us.rd.yahoo.com - March 30 at 5:28 AM
finance.yahoo.com logoTakeda Announces Ricardo Marek as New President of Emerging Markets Business Unit
au.finance.yahoo.com - March 30 at 5:28 AM
us.rd.yahoo.com logoTakeda and TiGenix Report New Data Highlighting Maintenance of Long-Term Remission of Complex Perianal Fistulas in Crohn’s Disease Patients with Cx601
us.rd.yahoo.com - February 17 at 7:03 PM
finance.yahoo.com logoFive-Year Open-Label Prospective Study Data Presented at the 12th Congress of European Crohn's and Colitis Organisation (ECCO) Provides Information on the Long-Term Use of Vedolizumab in Adult Patients with Moderate to Severely Active Ulcer
finance.yahoo.com - February 17 at 7:03 PM
finance.yahoo.com logoTakeda Presents $1 Million Gift to the Koch Institute for Integrative Cancer Research at MIT to Support Immuno-oncology Research
au.finance.yahoo.com - February 9 at 6:11 AM
ft.com logo[$$] US biotech Ovid to develop Takeda epilepsy drug in outsourcing tie-up
www.ft.com - January 19 at 4:55 AM
finance.yahoo.com logo7:34 am Takeda Pharma & Ovid Therapeutics announce innovative clinical development and commercialization collaboration for TAK-935 in rare pediatric epilepsies
finance.yahoo.com - January 19 at 4:54 AM
finance.yahoo.com logoTakeda and Ovid Therapeutics Announce Innovative Clinical Development and Commercialization Collaboration for TAK-935 in Rare Pediatric Epilepsies
au.finance.yahoo.com - January 19 at 4:54 AM
us.rd.yahoo.com logoMaverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies
us.rd.yahoo.com - January 12 at 3:20 AM
blogs.barrons.com logoTakeda Buys Ariad For $5.2 Billion: A Good Deal?
blogs.barrons.com - January 10 at 2:12 AM
nasdaq.com logoTakeda To Buy ARIAD For $24.00/shr; Accretive To FY18 Underlying Core Earnings
www.nasdaq.com - January 10 at 2:12 AM
bizjournals.com logoUW spinout wins $35M deal to develop therapy for celiac disease
www.bizjournals.com - January 7 at 6:02 AM
us.rd.yahoo.com logoTakeda and PvP Biologics Announce Development Agreement around Novel Therapeutic for Celiac Disease
us.rd.yahoo.com - January 6 at 6:09 AM
finance.yahoo.com logoGEMINI II & III Post-hoc Analysis Reports Clinical Benefits of Vedolizumab
finance.yahoo.com - December 9 at 8:07 PM
seekingalpha.com logoValeant: Avoid Post Salix/Takeda Deal Breakdown
seekingalpha.com - December 2 at 11:08 AM
finance.yahoo.com logoCerevance Launched with New Technology, Drug Portfolio and $36M in Cash to Tackle Brain Diseases
au.finance.yahoo.com - December 2 at 11:08 AM
investopedia.com logoValeant Stock Plunges 11% on Failed Salix Sale (VRX)
www.investopedia.com - December 1 at 9:47 AM
finance.yahoo.com logoValeant Said to Plan to Keep Salix After Takeda Deal Falls Apart
finance.yahoo.com - November 30 at 11:36 PM
bloomberg.com logoValeant Said to Keep Salix After Takeda Deal Falls Apart
www.bloomberg.com - November 30 at 11:36 PM
finance.yahoo.com logoTakeda's talks to acquire Valeant's Salix stall-sources
finance.yahoo.com - November 30 at 11:36 PM
finance.yahoo.com logoTakeda to Invest More Than 100 Million Euros in Dengue Vaccine Manufacturing Plant in Germany
au.finance.yahoo.com - November 30 at 10:22 AM
us.rd.yahoo.com logoNINLARO™ (ixazomib) Receives Conditional Approval from the European Commission to Treat Multiple Myeloma
us.rd.yahoo.com - November 29 at 10:51 AM
us.rd.yahoo.com logo3:19 am Takeda Pharma receives conditional approval for NINLARO from the European Commission
us.rd.yahoo.com - November 29 at 10:51 AM
seekingalpha.com logoValeant: Salix Rumors Send Sum-Of-The Parts Valuation Below $1
seekingalpha.com - November 24 at 7:48 PM
finance.yahoo.com logoAstraZeneca's Symbicort Positive in Pediatric Asthma Study
finance.yahoo.com - November 14 at 8:09 PM
finance.yahoo.com logoTakeda and the New York Academy of Sciences to Honor Commitment to Innovation in Key Areas of Therapeutic Focus
au.finance.yahoo.com - November 10 at 11:27 AM
seekingalpha.com logoValeant: $50-$70 After Salix Sale
seekingalpha.com - November 3 at 7:55 PM
finance.yahoo.com logoTakeda to Present Broad Range of Clinical Data During 58th American Society of Hematology Annual Meeting
au.finance.yahoo.com - November 3 at 12:12 PM
benzinga.com logoValeant's Potential Salix Sale Appears To Be A Positive
www.benzinga.com - November 2 at 8:20 PM
wsj.com logo[$$] Japan’s Takeda Pharmaceutical Seeks to Expand Overseas
www.wsj.com - November 2 at 8:20 PM

Social

Chart

Takeda Pharmaceutical (TKPYY) Chart for Tuesday, June, 27, 2017

This page was last updated on 6/27/2017 by MarketBeat.com Staff